Breast cancer management in the era of Covid-19; key issues, contemporary strategies, and future implications
Safayet Ullah Prodhan, AHM and Islam, Dewan Zubaer and Khandker, Shahad Saif and Jamiruddin, Mohd Raeed and Abdullah, Adnan and Godman, Brian and Opanga, Sylvia and Kumar, Santosh and Sharma, Paras and Adnan, Nihad and Pisana, Alice and Haque, Mainul (2023) Breast cancer management in the era of Covid-19; key issues, contemporary strategies, and future implications. Breast Cancer: Targets and Therapy, 2023 (15). pp. 51-89. ISSN 1179-1314 (https://doi.org/10.2147/BCTT.S390296)
Preview |
Text.
Filename: Prodhan_etal_BCTT_2023_Breast_cancer_management_in_the_era_of_covid_19.pdf
Final Published Version License: Download (2MB)| Preview |
Abstract
During the COVID-19 pandemic, several priority diseases were not getting sufficient attention. Whilst breast cancer is a fatal disease affecting millions worldwide, identification and management of these patients did not initially attract critical attention to minimize the impact of lockdown, post-lockdown, and other measures. Breast cancer patients' conditions may not remain stable without proper care, worsening their prognosis. Proper care includes the timely instigation of surgery, systemic therapy, and psychological support. This includes low- and middle-income countries where there are already concerns with available personnel and medicines to adequately identify and treat these patients. Consequently, there was a need to summarize the current scenario regarding managing breast cancer care during COVID-19 across all countries, including any guidelines developed. We systematically searched three scientific databases and found 76 eligible articles covering the medical strategies of high-income countries versus LMICs. Typically, diagnostic facilities in hospitals were affected at the beginning of the pandemic following the lockdown and other measures. This resulted in more advanced-stage cancers being detected at initial presentation across countries, negatively impacting patient outcomes. Other than increased telemedicine, instigating neo-adjuvant endocrine therapy more often, reducing non-essential visits, and increasing the application of neo-adjuvant chemotherapy to meet the challenges, encouragingly, there was no other significant difference among patients in high-income versus LMICs. Numerous guidelines regarding patient management evolved during the pandemic to address the challenges posed by lockdowns and other measures, which were subsequently adopted by various high-income countries and LMICs to improve patient care. The psychological impact of COVID-19 and associated lockdown measures, especially during the peak of COVID-19 waves, and the subsequent effect on the patient's mental health must also be considered in this high-priority group. We will continue to monitor the situation to provide direction in future pandemics.
-
-
Item type: Article ID code: 83889 Dates: DateEvent27 January 2023Published19 January 2023AcceptedSubjects: Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer) Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 27 Jan 2023 09:43 Last modified: 11 Nov 2024 17:48 URI: https://strathprints.strath.ac.uk/id/eprint/83889